Welcome to our dedicated page for REVIVE THERAPEUTICS news (Ticker: RVVTF), a resource for investors and traders seeking the latest updates and insights on REVIVE THERAPEUTICS stock.
Revive Therapeutics Ltd. develops specialty life sciences programs focused on infectious diseases and medical countermeasures. Company news commonly centers on Bucillamine, including intellectual-property filings, granted patent coverage, and research updates on its potential use in infectious diseases and nerve-agent exposure.
Revive updates also cover work with Defence R&D Canada – Suffield Research Centre, botanical research compounds, molecular hydrogen therapeutic programs, and financing activity. Capital-structure news includes private placements, debt settlement, unit issuances, common share purchase warrants, compensation options, and the use of proceeds for working capital and trade payables.
Revive Therapeutics (RVVTF) on September 15, 2026 outlined a strategy to expand the intellectual property and regulatory portfolio around its drug bucillamine across medical countermeasures and rare diseases.
The plan focuses on pursuing additional patents and international protection, growing an orphan-disease portfolio beyond existing U.S. FDA Orphan Drug Designations for cystinuria and ischemia-reperfusion injury in liver transplantation, and targeting government programs that may fund, procure or stockpile bucillamine. The company also highlights ongoing collaboration with Defence Research and Development Canada, where positive findings were reported in a nerve-agent exposure model, and pending patents for use in infectious diseases and chemical-warfare contexts.
Revive Therapeutics (OTCQB:RVVTF) announced a proposed debt settlement under which it intends to issue up to 1,221,516 common shares at a deemed price of $0.05 per share. The issuance would settle an aggregate of $61,061 in outstanding trade payables owed to two arm's length creditors.
The settlement shares will be issued in accordance with Canadian Securities Exchange policies and will be subject to a statutory hold period of four months and one day. Completion is conditional on receiving necessary regulatory approvals, including CSE acceptance, and is expected to close no earlier than five business days from the announcement date.
Revive Therapeutics (OTCQB:RVVTF) outlined a strategy to build a focused biodefence and pandemic-preparedness therapeutics portfolio led by bucillamine. The plan is anchored on positive August 12, 2026 DRDC animal-model findings in nerve-agent exposure, where bucillamine appeared comparable to N-acetylcysteine on a key hippocampal endpoint and showed no pulmonary hemorrhage in treated animals.
The company aims to advance bucillamine as a potential medical countermeasure through government-backed research, non-dilutive funding, co-development, licensing, procurement and stockpiling opportunities in Canada, the United States and allied markets. Revive holds Canadian Patent No. 3,172,170 for infectious-disease uses of bucillamine (expiry March 16, 2041) and has pending patent applications for chemical-warfare-agent exposure.
Revive’s execution plan starts with confirmatory DRDC studies scheduled to begin in Q4 2026, building government and regulatory pathways, expanding intellectual property, and partnering for development and scale. The company is also evaluating complementary therapeutics to create a coherent medical-countermeasure portfolio across chemical, biological and pandemic threats.
Revive Therapeutics (OTCQB:RVVTF) reported that its Board authorized the grant of an aggregate 15,500,000 incentive stock options to directors, officers and consultants. The options have an exercise price of $0.05 per share and a term of five years. All options were issued under the company’s 10% rolling stock option plan and remain subject to the plan terms and Canadian Securities Exchange requirements.
Revive Therapeutics (OTCQB:RVVTF) reported positive results from a Defence Research and Development Canada (DRDC) study evaluating bucillamine in an animal model of nerve-agent exposure. The study compared bucillamine to N-acetylcysteine (NAC), examining clinical signs, seizure activity and preservation of hippocampal GABA receptor post-synaptic density.
Animals pretreated with bucillamine or NAC both showed preserved GABA receptor post-synaptic density versus controls, with bucillamine appearing comparable to NAC on this endpoint. No pulmonary hemorrhage was observed in the bucillamine group, while it was observed in the NAC group; no cerebral hemorrhage occurred in either group. DRDC plans additional confirmatory bucillamine studies starting in Q4-2026, which may support Revive’s efforts to pursue development, funding and collaboration opportunities in biodefence and pandemic preparedness.
Revive Therapeutics (OTCQB:RVVTF) closed the first tranche of its previously announced non-brokered private placement, raising gross proceeds of $246,920 through the issuance of 7,716,250 units at $0.032 per unit. Each unit includes one common share and one warrant exercisable at $0.05 for 36 months.
According to the company, proceeds will be used primarily for working capital. Revive paid finders $17,433.60 and issued 537,300 broker warrants with a $0.05 exercise price and 36‑month term. All securities are subject to a four-month‑and‑one‑day hold period, and further closings may occur.
Revive Therapeutics (OTCQB:RVVTF) announced a proposed non-brokered private placement of up to 31,250,000 units at $0.032 per unit, for maximum gross proceeds of about $1,000,000.
Each unit includes one common share and a three‑year warrant exercisable at $0.05, with proceeds earmarked for working capital.
Revive Therapeutics (OTCQB:RVVTF) outlined a strategic expansion of its bucillamine program across infectious diseases, defence and biothreat medical countermeasures. Plans include new preclinical studies, pursuit of government and defence partnerships, and exploration of stockpiling and non-dilutive funding opportunities.
Revive highlighted a granted Canadian patent for infectious diseases (expiring March 16, 2041), North American patent filings for nerve-agent exposure, an ongoing collaboration with Defence R&D Canada, and bucillamine’s multi-decade clinical history as foundations for building a broader medical countermeasure platform.
Revive Therapeutics (OTCQB:RVVTF) announced North American patent filings for bucillamine in nerve agent exposure and a granted Canadian patent for infectious diseases. The Canadian patent (No. 3,172,170) was granted March 10, 2026 and expires March 16, 2041. U.S. and Canadian national phase filings under PCT/CA2024/000008 carry U.S. application 19/518,001 and Canadian application 3,304,264.
The moves expand Revive's IP in medical countermeasures and infectious diseases, support partnering/licensing potential, and align with an active research collaboration with Defence R&D Canada — Suffield Research Centre (DRDC).
Revive Therapeutics (OTCQB: RVVTF; CSE: RVV) provided an update on its collaborative research study with Defence R&D Canada – Suffield Research Centre (DRDC) evaluating Bucillamine as a potential treatment for nerve agent–induced brain injury. The company said the DRDC-led study is expected to conclude with results in January 2026. Any findings will be released only with the express authorization of DRDC. Revive indicated it will continue to provide updates as the study advances toward completion.